In clinical studies, adverse events common to intra-articular treatment were comparable between SUPARTZ FX and saline-treated patients16,22,38,39

  • In these studies, more people discontinued treatment with saline placebo than those who received SUPARTZ FX therapy38
  • Pseudoseptic (acute inflammatory) reactions have NOT been reported in 20 prospective randomized controlled trials of
    SUPARTZ FX therapy41
  • The FDA reviewed data on more than 8,000 patients prior to approving SUPARTZ FX in the United States37

SUPARTZ FX offers a safety profile similar to saline placebo

Adverse events occurred at similar rates in patients treated with SUPARTZ FX and those treated with a saline placebo in an integrated analyses of multiple clinical studies. No serious injection site adverse events were reported and no allergic reactions due to SUPARTZ FX were reported.38

  • Results of integrated analysis of 5 clinical trials with 1,155 patients showed SUPARTZ FX had adverse events and discontinuation rates similar to saline placebo
  • Comparable incidence of adverse events following SUPARTZ FX versus saline placebo16,38

Safety Chart

  • Discontinuation rates due to adverse events were 1.8% for SUPARTZ and 3.2% for placebo38

Safety Chart

  • No reports of pseudoseptic reactions in the scientific literature‡41

‡Does not include current prescribing experience.

SUPARTZ FX contains virtually no detectable impurities

  • A study of impurities in hyaluronic acid (HA) products found that SUPARTZ FX has less protein content than other HA products42

Safety Chart

  • SUPARTZ FX also had significantly less bacteria endotoxin content and significantly less nucleic acids/DNA content compared with other HA products42

See additional SUPARTZ FX Resources

All registered trademarks are the properties of their respective companies.